CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk

Abstract

The length of the polymorphic CAG repeat in the N-terminal of the androgen receptor (AR) gene is inversely correlated with the transactivation function of the AR. Some studies have indicated that short CAG repeats are related to higher risk of prostate cancer. We performed a case–control study to investigate relations between CAG repeat length and prostate cancer risk, tumour grade, tumour stage, age at diagnosis and response to endocrine therapy. The study included 190 AR alleles from prostate cancer patients and 186 AR alleles from female control subjects. All were whites from southern Sweden. The frequency distribution of CAG repeat length was strikingly similar for cases and controls, and no significant correlation between CAG repeat length and prostate cancer risk was detected. However, for men with non-hereditary prostate cancer (n = 160), shorter CAG repeats correlated with younger age at diagnosis (P = 0.03). There were also trends toward associations between short CAG repeats and high grade (P = 0.07) and high stage (P = 0.07) disease. Furthermore, we found that patients with long CAG repeats responded better to endocrine therapy, even after adjusting for pretreatment level of prostate-specific antigen and tumour grade and stage (P = 0.05). We conclude that short CAG repeats in the AR gene correlate with young age at diagnosis of prostate cancer, but not with higher risk of the disease. Selection of patients with early onset prostate cancer in case–control studies could therefore lead to an over-estimation of the risk of prostate cancer for men with short CAG repeats. An association between long CAG repeats and good response to endocrine therapy was also found, but the mechanism and clinical relevance are unclear.

Change history

  • 16 November 2011

    This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication

References

  1. Bratt, O, Kristoffersson, U, Lundgren, R & Olsson, H (1999) Familial and hereditary prostate cancer in southern Sweden. A population-based case–control study. Eur J Cancer 35: 272–277

  2. Bratt, O, Kristoffersson, U, Olsson, H & Lundgren, R (1998) Clinical course of early onset prostate cancer with special reference to family history as a prognostic factor. Eur Urol 34: 19–24

  3. Carter, BS, Beaty, TH, Steinberg, GD, Childs, B & Walsh, PC (1992) Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 89: 3367–3371

  4. Carter, BS, Bova, G, Beaty, TH, Steinberg, GD, Childs, B, Isaacs, W & Walsh, PC (1993) Hereditary prostate cancer: epidemiologic and clinical features. J Urol 150: 797–802

  5. Chamberlain, N, Driver, E & Miesfeld, R (1994) The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acid Res 22: 3181–3186

  6. Dijkman, G & Debruyne, F (1996) Epidemiology of prostate cancer. Eur Urol 30: 281–295

  7. Giovannucci, E, Stampfer, M, Krithivas, K, Brown, M, Brufsky, A, Talcott, J, Hennekens, C & Kantoff, P (1997) The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 94: 3320–3323

  8. Grönberg, H, Damber, J-E, Jonsson, H & Lenner, P (1994) Patient age as a prognostic factor in prostate cancer. J Urol 152: 892–895

  9. Hakimi, J, Rondinelli, R, Schoenberg, M & Barrack, E (1996) Andogen-receptor gene structure and function in prostate cancer. World J Urol 14: 329–337

  10. Hakimi, J, Schoenberg, M, Rondinelli, R, Piantadosi, S & Barrack, E (1997) Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. Clin Cancer Res 3: 1599–1608

  11. Hardy, D, Scher, H, Bogenreider, T, Sabbatini, P, Zhang, Z-F, Nanus, D & Catterall, J (1996) Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J Clin Endocrinol Metab 81: 4400–4405

  12. Hayes, RB, Liff, JM, Pottern, LM, Greenberg, RS, Schoenberg, JB, Schwartz, AG, Swanson, GM, Silverman, DT, Morris Brown, L, Hoover, RN & Fraumeni, JF (1995) Prostate cancer risk in U.S blacks and whites with a family history of cancer. Int J Cancer 60: 361–364

  13. Ingles, S, Ross, R, Yu, M, Irvine, R, La Pera, G, Haile, R & Coetzee, G (1997) Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 89: 166–170

  14. Irvine, R, Yu, M, Ross, R & Coetzee, G (1995) The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 55: 1937–1940

  15. Kazemi-Esfarjani, P, Trifiro, M & Pinsky, L (1995) Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the (CAG)n-expanded neuronopathies. Hum Mol Genet 4: 523–527

  16. Keetch, DW, Rice, JP, Suarez, BK & Catalona, WJ (1995) Familial aspects of prostate cancer: a case control study. J Urol 154: 2100–2102

  17. La Spada, A, Wilson, E, Lubahn, D, Harding, A & Fischbeck, K (1991) Androgen receptor gene mutations in X-linked spinal and bulbar muscular dystrophy. Nature 352: 77–79

  18. Lesko, S, Rosenberg, L & Shapiro, S (1996) Family history and prostate cancer risk. Am J Epidemiol 144: 1041–1047

  19. Lubahn, D, Brown, T, Simental, J, Higgs, H, Migeon, C, Wilson, E & French, F (1989) Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity. Proc Natl Acad Sci USA 86: 9534–9538

  20. Monroe, K, Yu, M, Kolonel, L, Coetzee, G, Wilkens, L, Ross, RK, & Henderson, B (1995) Evidence of an X-linked or recessive genetic component to prostate cancer risk. Nature Med 1: 827–829

  21. Narod, S, Dupont, A, Cusan, L, Diamond, P, Gomez, J-L, Suburu, R & Labrie, F (1995) The impact of family history on early detection of prostate cancer (letter). Nature Med 1: 99–101

  22. Rinker-Schaeffer, C, Partin, A, Isaacs, W, Coffey, D & Isaacs, J (1994) Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells. Prostate 25: 249–265

  23. Ross, R, Pike, M, Coetzee, G, Reichardt, J, Yu, M, Feigelson, H, Stanczyk, F, Kolonel, L & Henderson, B (1998) Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 58: 4497–4504

  24. Schaid, D, McDonnel, S, Blute, M & Thibodeau, S (1998) Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet 62: 1425–1438

  25. Smith, JR, Freije, D, Carpten, JD, Grönberg, H, Xu, J & Isaacs, SD et al (1996) Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274: 1371–1374

  26. Stanford, J, Just, J, Gibbs, M, Wicklund, K, Neal, C, Blumenstein, B & Ostrander, E (1997) Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 57: 1194–1198

  27. Tut, T, Ghadeesy, F, Trifiro, M, Pinsky, L & Yong, E (1997) Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility. J Clin Endocrinol Metab 82: 3777–3782

  28. Whittemore, AS, Wu, AH, Kolonel, LN, John, EM, Gallagher, RP, Howe, GR, West, DW, Teh, C-Z & Stamey, T (1995) Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. Am J Epidemiol 141: 732–740

  29. Xu, J, Meyers, D, Freije, D, Isaacs, S & Wiley, K et al (1998) Evidence for a prostate cancer susceptibility locus on the X chromosome (letter). Nature Genetics 20: 175–179

Download references

Author information

Correspondence to O Bratt.

Rights and permissions

From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

Reprints and Permissions

About this article

Cite this article

Bratt, O., Borg, Å., Kristoffersson, U. et al. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br J Cancer 81, 672–676 (1999). https://doi.org/10.1038/sj.bjc.6690746

Download citation

Keywords

  • prostatic neoplasms
  • cancer risk
  • androgen receptor
  • genetics
  • epidemiology

Further reading